Drug Firm Spark Therapeutics Will Charge $850000 for Vision-Loss Gene Therapy – Wall Street Journal
Wall Street Journal |
Drug Firm Spark Therapeutics Will Charge $850000 for Vision-Loss Gene Therapy
Wall Street Journal Spark Therapeutics Inc. ONCE 4.60% said it would charge $850,000 a patient for a pioneering new treatment for a hereditary form of vision loss—below the $1 million price tag the company had considered, but still a milestone for ever-rising drug prices … |
